What is the recommended treatment for anti‑neutrophil cytoplasmic antibody (ANCA)‑associated recurrent scleritis with peripheral ulcerative keratitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 5, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Treatment of ANCA-Associated Recurrent Scleritis with Peripheral Ulcerative Keratitis

For ANCA-associated recurrent scleritis with peripheral ulcerative keratitis, treat with rituximab as the preferred agent for remission reinduction, combined with high-dose glucocorticoids. This represents organ-threatening disease requiring aggressive systemic immunosuppression to prevent vision loss and globe perforation.

Remission Induction Strategy

Since this is recurrent disease, the 2024 KDIGO guidelines explicitly state that patients with relapsing AAV should be reinduced preferably with rituximab 11. The 2024 EULAR recommendations similarly prioritize rituximab for relapsing disease 2.

Rituximab Dosing for Induction

  • 375 mg/m² weekly for 4 weeks 1
  • Alternative: 1000 mg infusion at weeks 0 and 2 (can be combined with cyclophosphamide 15 mg/kg at weeks 0 and 2 for severe disease) 1

Glucocorticoid Regimen

Use weight-based dosing with rapid taper 1:

  • Week 1: 50 mg (<50 kg), 60 mg (50-75 kg), or 75 mg (>75 kg)
  • Week 2: 25 mg, 30 mg, or 40 mg respectively
  • Continue structured taper to 5 mg daily by week 19-22
  • Maintain 5 mg daily through week 52, then follow local practice

Why Rituximab Over Cyclophosphamide

The RITAZAREM trial demonstrated >90% remission rates by 4 months in relapsing AAV treated with rituximab 1. Rituximab is particularly preferred because:

  • Higher remission rates in relapsing patients compared to cyclophosphamide, especially for PR3-AAV 1
  • Avoids cumulative cyclophosphamide toxicity (doses >36g associated with malignancies) 1
  • Case reports specifically document successful treatment of refractory scleritis/peripheral ulcerative keratitis with rituximab after cyclophosphamide failure 34

Alternative if Rituximab Previously Failed

If rituximab was used for initial induction, consider switching to cyclophosphamide 11:

  • Oral: 2 mg/kg/day for 3 months (reduce to 1.5 mg/kg if age >60,1.0 mg/kg if age >70)
  • Intravenous: 15 mg/kg at weeks 0,2,4,7,10,13 (reduce to 12.5 mg/kg if age >60,10 mg/kg if age >70)

Adjunctive Considerations

Plasma Exchange

Consider adding plasma exchange if 11:

  • Rapidly progressive disease despite initial therapy
  • Severe necrotizing scleritis with impending perforation
  • Evidence suggests benefit in refractory disease 1

Surgical Intervention

Ophthalmologic collaboration is critical 35:

  • Amniotic membrane transplantation for corneal defects
  • Scleral patch grafting for impending perforation (required in 3/19 eyes in one series) 6
  • Conjunctival flap coverage with necrotic tissue removal and cryotherapy for necrotizing scleritis 7

Maintenance Therapy After Remission

Following successful reinduction, maintain remission with 11:

Rituximab maintenance (preferred for relapsing disease):

  • MAINRITSAN scheme: 500 mg × 2 at remission, then 500 mg at months 6,12,18
  • RITAZAREM scheme: 1000 mg at months 4,8,12,16 after first infusion

Alternative maintenance options (if rituximab contraindicated):

  • Azathioprine 1.5-2 mg/kg/day 1
  • Mycophenolate mofetil 2000 mg/day (divided doses) 1
  • Methotrexate (only if GFR >60 ml/min/1.73m²) 1

Continue low-dose glucocorticoids (5-7.5 mg/day) for 2 years, then taper by 1 mg every 2 months 11

Critical Pitfalls to Avoid

  1. Do not treat as isolated ocular disease: Scleritis with peripheral ulcerative keratitis in ANCA-positive patients represents systemic vasculitis requiring full systemic immunosuppression, not just topical therapy 56

  2. Do not delay treatment: Vision-threatening complications including globe perforation can occur rapidly 37

  3. Do not use maintenance-dose immunosuppression for active relapse: Relapses require full reinduction therapy, not simply increasing maintenance doses 11

  4. Ensure Pneumocystis jirovecii prophylaxis: Use trimethoprim-sulfamethoxazole with rituximab or cyclophosphamide plus high-dose glucocorticoids 2

  5. Monitor immunoglobulin levels: Check serum IgG before each rituximab course to detect secondary immunodeficiency 2

Multidisciplinary Management

This condition requires immediate ophthalmology-rheumatology collaboration 356. The 2024 EULAR and KDIGO guidelines emphasize management at centers with vasculitis expertise 12. Close ophthalmologic monitoring is essential as anatomical outcomes depend on aggressive acute management and adequate maintenance immunosuppression 6.

References

Related Questions

Is antineutrophil cytoplasmic antibody (ANCA) associated with scleritis or retinal involvement?
What alternative drug can be used instead of rituximab for peripheral ulcerative keratitis in a PR3‑ANCA‑positive patient?
Can ANCA (anti-neutrophil cytoplasmic antibody)-associated vasculitis have low serum complement C3 and C4, and what does the latest data show?
In a 17-year-old boy with a two-year history of unilateral vision loss and a self-settled partial retinal detachment, suspected vitreous-retinal vasculitis, and no systemic features, how significant is a low-positive cytoplasmic antineutrophil cytoplasmic antibody (C-ANCA) titer (moderate ++, 1:20) with a normal erythrocyte sedimentation rate (14 mm/h) and negative antinuclear antibody (ANA)?
What are the possible causes and recommended management for visible scleral blood vessels?
Can you explain the pathophysiology of cardio‑renal syndrome (CRS)?
A patient reports that ondansetron (Zofran) is controlling her nausea, but she is experiencing severe night sweats, vivid disturbing dreams, and persistent fatigue, likely due to missing her lisdexamfetamine (Vyvanse). What recommendations should be given?
What is the target hemoglobin (Hb) level during pregnancy?
What is the recommended anticoagulation regimen for a provoked pulmonary embolism?
What alternative drug can be used instead of rituximab for peripheral ulcerative keratitis in a PR3‑ANCA‑positive patient?
What antiepileptic prophylaxis regimen (drug, dose, and duration) is recommended for patients with moderate to severe traumatic brain injury (Glasgow Coma Scale ≤12) or intracranial hemorrhage?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.